Skip to main content
Premium Trial:

Request an Annual Quote

20/20, Novartis Collaborate on Tumor Protein Profiling

NEW YORK, Oct. 9 - 20/20 GeneSystems said today it is collaborating with Novartis to identify protein expression and activation patterns in tumor samples.

 

Novartis will supply 20/20 with tissue samples for the company to evaluate with its Protein Function Identification Layered Membranes technology in order to build protein profiles that can be used to classify tumor subtypes, according to 20/20.

 

Novartis, which will have early access to 20/20 technology, will provide 20/20 with funding, though details were not disclosed.

 

20/20 GeneSystems is based in Rockville, Md.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.